LSLawrence Serfaty

Lawrence Serfaty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lawrence Serfaty has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C‐related insulin resistance

    by M. Lemoine, S. Chevaliez, J. P. Bastard, L. Fartoux, O. Chazouillères, J. Capeau, J. M. Pawlotsky, L. Serfaty

    TNFα has been shown to play a role in hepatitis C virus (HCV)-induced insulin resistance (IR). Polymorphism of the IL28B gene that encodes IFN-lambda 3 may be associated with IR through modulation of TNFα. The aim of this study was to investigate the relationship between IL28B rs12979860 genotype, the level of TNFα activation and the degree of IR in patients with chronic hepatitis C. One hundred and thirty-three nondiabetic genotype 1 HCV-infected patients with biopsy proven noncirrhotic hepatitis C were investigated for IR (using HOMA index), IL28B rs12979860 genotype and fasting circulating levels of soluble receptor 1 of TNFα (sTNFR1) and adipokines: leptin, adiponectin and IL-6. The HOMA-IR was positively correlated with serum levels of leptin (r = 0.35, P < 0.0001) and sTNFR1 (r = 0.35, P < 0.0001) but not with IL-6 or adiponectin. IL28B rs12979860 CC genotype was observed in 35% patients. Genotype CC and nongenotype CC patients were similar in terms of HOMA-IR (means 1.6 ± 0.9 vs 1.7 ± 1.4) and had similar circulating levels of sTNFR1 and adipokines. Independent factors associated with IR were ferritin (OR = 1.002, P = 0.02), leptin (OR = 1.06, P = 0.02) and sTNFR1 (OR = 7.9, P = 0.04). This study suggests that in nondiabetic, noncirrhotic, HCV genotype 1-infected patients, there is no relationship between IL28B rs12979860 genotype and HOMA-IR or sTNFR1 level. HCV-related IR may be mediated through TNFα independent of IL28B genotype.


  • How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals

    by Lawrence Serfaty

    Second wave direct acting antivirals such as sofosbuvir, simeprevir and daclatasvir can be combined with pegylated interferon alpha and ribavirin (PEG-IFN/RBV) as triple therapy in patients with hepatitis C virus (HCV) infection. In patients with HCV genotype 1 (HCV-1), a PEG-IFN/RBV-based regimen with sofosbuvir is highly effective but the presence of cirrhosis and the non-CC IFNL3 genotype have been associated with a poorer response. A PEG-IFN/RBV-based regimen with simeprevir or daclatasvir is based on response-guided therapy and its efficacy depends on predictors of response to IFN. HCV-1 subtype is also a major predictor of response. In HCV-1a infected patients, the K80Q mutation in NS3 or the presence of NS5A variants at baseline are associated with poor response with simeprevir- or daclatasvir-containing regimens respectively. Thus, these regimens should be only used in HCV-1b patients with good predictors of response to IFN.


  • P1203 EFFICACY AND SAFETY OF TELAPREVIR-BASED TRIPLE THERAPY IN HIV/HCV COINFECTED VERSUS HCV MONOINFECTED PATIENTS: A MATCHED-COHORT STUDY

    by A. Pascale, A. Boyd, J. Bottero, H. Stitou, N. Valin, F. Benjelloun, O. Chazouilleres, P.-M. Girard, L. Serfaty, K. Lacombe

  • Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?

    by Lawrence Serfaty

    Boceprevir and telaprevir-based triple therapy is now the standard of care for the treatment of genotype 1 patients. However, dual therapy with pegylated interferon and ribavirin should be discussed in treatment-naïve patients with good predictors of response. A recent published trial has shown in non-cirrhotic patients with low viral load at baseline, similar efficacy of a 24-week course of dual therapy vs a 24-week course of boceprevir-based triple therapy in case of rapid virological response. Accordingly, addition of protease inhibitor should be discussed after 4 weeks of dual therapy in this easy-to-treat population.


  • Altered hepatic expression of SREBP-1 and PPARγ is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients

    by Maud Lemoine, Véronique Barbu, Pierre Marie Girard, Minji Kim, Jean-Philippe Bastard, Dominique Wendum, François Paye, Chantal Housset, Jacqueline Capeau, Lawrence Serfaty

    Background: HIV-infected patients with HAART-related lipodystrophy are frequently insulin resistant and at risk of non-alcoholic fatty liver disease (NAFLD) with steatohepatitis (NASH). The transcription factors, peroxisome proliferator activated receptors (PPARα, PPARγ1/PPARγ2) and sterol regulatory element binding proteins (SREBP-1) regulate liver lipid metabolism. Here, we examined whether their expression was modified and related to liver injury in HIV-infected patients. Methods: Fourteen HAART-treated HIV patients (nine with and five without insulin resistance) who had liver biopsy because of unexplained elevated transaminases were compared with nine non-HIV age-and body mass index-matched patients with NAFLD and 10 controls without steatosis. Hepatic expression of PPARs and SREBP-1 was assessed by real time reverse transcriptase-polymerase chain reaction. Results: Liver histology showed NASH in six of nine insulin-resistant lipodystrophic and two of five non-insulin-resistant HIV patients. Compared with NAFLD or control subjects, expression of SREBP-1 was significantly higher only in HIV-insulin-resistant patients (P = 0.04 and P = 0.02) whereas, compared to controls, HIV-insulin-resistant, HIV-non-insulin-resistant and NAFLD patients had lower expressions of PPARγ1 (P = 0.03, P = 0.05 and P = 0.01) and PPARγ2 (P = 0.04, P = 0.05 and P = 0.01). Among HIV patients, the percentage of steatosis was positively correlated with SREBP-1 expression (r = 0.62, P = 0.04) whereas the score of fibrosis was inversely correlated with PPARγ1 and PPARγ2 expression (r = −0.57, P = 0.03 and r = −0.6, P = 0.02, respectively). Conclusion: Insulin-resistant lipodystrophic HIV-infected patients may develop NASH. Steatosis is associated with overexpression of SREBP-1 and fibrosis with decreased expression of PPARγ1 and PPARγ2. These results suggest that altered expression of SREBP-1 and PPARγ could contribute to the pathogenesis of steatosis and fibronecrotic changes in insulin-resistant lipodystrophic patients.


  • Open Access

    Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

    by L Fartoux, A Poujol-Robert, J Guéchot, D Wendum, R Poupon, L Serfaty

    Background: Insulin resistance is a frequent feature of chronic hepatitis C. Whether insulin resistance could be the cause or consequence of steatosis and fibrosis is unknown. The ability of HCV genotype 3 to promote steatosis by itself provides an unique opportunity to answer this question. Aims: The aim of the present study was to assess the relationships between insulin resistance, steatosis, and fibrosis according to genotype in 141 non-diabetic patients with biopsy proven non-cirrhotic chronic hepatitis C. Methods: All patients had fasting serum glycaemia and insulinaemia measurements. Insulin resistance was evaluated using the homeostasis model assessment (HOMA IR) method. Liver steatosis was determined according to hepatitis C virus genotype (1 or 3). Logistic regression and multivariate regression analysis were used to identify variables independently associated with insulin resistance, fatty liver, and fibrosis. Results: Although steatosis and fibrosis were more severe in genotype 3 patients, median HOMA IR was significantly higher in patients with genotype 1 related steatosis than in those with genotype 3 related steatosis (2.1 v 1; p = 0.001). Independent risk factors for steatosis were insulin resistance in genotype 1 patients (p = 0.001) and viral load in genotype 3 patients (p = 0.003). Among genotype 1 patients, independent parameters associated with insulin resistance were age (p = 0.04) and steatosis (p = 0.004). Steatosis was associated with more severe fibrosis whatever the genotype (p = 0.002). Among genotype 1 patients, although there was a significant relationship between circulating insulin level and fibrosis stage (p = 0.006), only steatosis and inflammatory score were independently associated with fibrosis. Conclusion: This study shows that insulin resistance is the cause rather than the consequence of steatosis and fibrosis in genotype 1 patients and that increased circulating insulin is a risk factor for fibrosis through insulin resistance induced steatosis.


  • L'érythromycine intraveineuse améliore le lavage gastrique au cours de l'hémorragie digestive haute (hdh): essai prospectif, controlé, randomisé

    by N. Carbonell, L. Becquemont, P. Y. Boelle, A. Daguenel, V. Godard, L. Serfaty, N. Best, R. Poupon

    Rationnel Au cours de l'hémorragie digestive haute (HDH), la gastroscopie est rendue difficile par la présence de sang dans l'estomac. Le but de l'étude était de montrer si l'érythromycine, associée au lavage gastrique, pouvait améliorer la vacuité gastrique et ainsi améliorer la qualité de l'endoscopie. Patients et Méthodes: Entre novembre 2000 et novembre 2002 les patients admis pour une HDH avec une hémoglobine < à 11g/dl, du sang à la sonde gastrique, et une endoscopie prévue dans les 8 heures étaient inclus dans l'étude. Les patients avaient un lavage gastrique et étaient randomisés entre une injection intra veineuse sur 30 minutes soit de 250mg d'E soit de sérum physiologique comme placebo (P). Les produits étaient reconstitués par la pharmacien de l'hôpital en aveugle de l'équipe soignante et de l'endoscopiste. La randomisation était stratifiée selon la présence ou non d'une hypertension portale. Le critère de jugement principal était la persistance de caillot dans l'estomac lors de l'endoscopie. Les caillots étaient définis par tout caillot ne pouvant être aspiré par le canal opérateur de l'endoscope. L'endoscopiste notait l'examen complet (tout l'estomac et le duodénum vu) ou incomplet, la durée de l'examen et utilisait une échelle visuelle analogique pour estimer la qualité de la préparation. Les critères de jugement secondaires étaient la possibilité de poser un diagnostic étiologique, de faire un geste hémostatique, le recours à une seconde endoscopie dans les 48heures, le nombre de culots transfusés, et la durée d'hospitalisation. La tolérance de l'examen (bonne, moyenne ou mauvaise) et la présence de contractions gênant l'examen étaient rapportées. Résultats: 99 patients étaient inclus dans l'étude, 49 dans le groupe E, 50 dans le groupe P. L'age, le délai entre le début de l'hémorragie et l'admission, la présence d'un choc, le niveau d'hémoglobine, le nombre de culot transfusé et l'origine du saignement étaient identiques dans les 2 groupes. 66 patients avaient une cirrhose. La persistance de caillots était plus fréquente dans le groupe P (52%) que E (30%) pConclusion: Au cours de l'HDH, l'E iv diminue la présence de caillot dans l'estomac et permet un examen endoscopique plus complet de l'estomac. Ce traitement est bien toléré mais ne modifie pas le pronostic de ces patients.

  • Ursodeoxycholic Acid Therapy and the Risk of Colorectal Adenoma in Patients With Primary Biliary Cirrhosis: An Observational Study

    by Lawrence Serfaty, Antoine De Leusse, Olivier Rosmorduc, Benoit Desaint, Jean-Francois Flejou, Olivier Chazouilleres, Renée E. Poupon, Raoul Poupon

    Ursodeoxycholic acid (UDCA) is the first–line treatment for primary biliary cirrhosis (PBC). The long–term administration of UDCA might indirectly favor colon carcinogenesis by increasing the fecal excretion of secondary bile acids or, in contrast, it might inhibit colon carcinogenesis, as demonstrated in animal models. In patients with PBC, we examined the effect of prolonged UDCA administration on the prevalence and recurrence of colorectal adenoma and on the proliferation of colon epithelial cells. One hundred fourteen patients (103 women, 11 men; mean age, 55 years) with PBC, were enrolled in a colonoscopic surveillance program. The prevalence of colon adenoma was compared in patients already treated with UDCA (mean duration 46 months) at the time of colonoscopy (treated group, n = 52) and in patients undergoing colonoscopy just prior to treatment initiation (untreated group, n = 62). The recurrence of adenoma following removal (mean follow–up, 35 months) was compared between UDCA–treated patients and appropriate age– and gender–matched controls (2/1) selected from a cohort of 205 patients undergoing polypectomy. Epithelial cell proliferation was assessed using anti–Ki67 antibodies on colon biopsies from both treated and untreated patients. Treated and untreated patients displayed similar demographic characteristics. The prevalence of colorectal adenomas was 13% in the treated group versus 24% in the untreated group (P = .16). The colon epithelial cell proliferation index was significantly lower in treated patients than in untreated patients (P = .001). Following removal of the adenoma, the probability of recurrence was significantly lower in patients treated with UDCA than in controls (7% vs. 28% at 3 years, P = .04). In conclusion, this study suggests that, in patients with PBC, the prolonged administration of UDCA (1) is not associated with an increased prevalence of colorectal adenomas, and (2) significantly decreases the probability of colorectal adenoma recurrence following removal. These results are strengthened by the significant reduction in colon epithelial cell proliferation seen in patients treated with UDCA.


    • 29 June 2002
      • Vol. 31  (23) , 1083-4

    [Cholestatic icterus induced by the administration of fusidic acid in a cirrhotic patient].

    by N Carbonell, D Thabut, P Podevin, M Biour, L Serfaty, R Poupon

    Fucidic acid is an antibiotic essentially used to treat staphylococcal infections. Its chemical structure is very similar to that of bilary acids and hence implies competitive mechanisms between their elimination and metabolization. A patient with a past history of alcohol-induced cirrhosis was treated with fucidic acid for a Staphylococci aureus urinary infection. On day 2 of treatment a conjugate bilirubine icterus appeared. There was no argument to suggest a decompensation of the icterus. The icterus disappeared on suspension of fucidic acid. The occurrence of an icterus in a cirrhotic patient may evoke decompensation of the hepatopathy and an extensive exploration must be made. A thorough survey of all drug administration must be made. Notably, the possibility of the occurrence of a connective bilirubin icterus during treatment with fucidic acid must be known. The icterus always regresses on withdrawal of treatment and this etiology must be evoked before conducting invasive examinations.